Background/Aim: Drozitumab is a fully human agonistic monoclonal antibody that binds to
death receptor DR5 and induces apoptosis. However, drozitumab resistance is a major …

Apomab, a fully human agonistic DR5 monoclonal antibody, triggers apoptosis through
activation of the extrinsic apoptotic signaling pathway. In this study, we assessed the …

3582 Background: Apomab, a fully human affinity-matured IgG1 monoclonal antibody, is a
DR5 pro-apoptotic receptor agonist that triggers the extrinsic pathway of apoptosis. DR5 is …

Abstract Death receptor 5 (DR5) is an attractive target for cancer therapy due to its broad
upregulated expression in multiple cancers and ability to directly induce apoptosis. Though …

Purpose: Rhabdomyosarcoma (RMS) is a common pediatric soft-tissue tumor. In this study,
we evaluated the efficacy and selectivity of drozitumab, a death receptor DR5-targeted …

The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces
apoptosis via death receptor (DR) 4 or DR5 preferentially in cancer cells, and not in normal …

Induction of apoptosis plays a crucial role in the response of tumors to treatment. Thus, we
investigated the pharmacodynamics and tumor saturation kinetics of a death receptor 5 …

Abstract Purpose: CS-1008 (tigatuzumab; phase I/II), an antihuman death receptor 5 (DR5)
agonist, induces apoptosis and has cytotoxic activity against human cancer cell lines. This …

Background The antitumor activity of CS-1008, a humanized agonistic anti-human death
receptor (DR) 5 antibody, was investigated in preclinical models. Materials and methods …

Previously, we found that GST-tagged tumor necrosis factor-related apoptosis inducing
ligand preferentially killed triple-negative breast cancer (TNBC) cells with a mesenchymal …